Degree of response and the duration of survival of patients treated with mitogen-activated protein kinase (MAPK) inhibitors are highly variable. A recent study found sex, serum LDH, BRAF genotype, and primary melanoma ulceration status to be independent factors associated with treatment outcomes. Patients with a complete response to treatment have the best survival, but relapses still occur.
- Cohort: 142 consecutive immunotherapy- and MAPK inhibitor-naive patients with BRAF-mutant metastatic melanoma treated during clinical trials with BRAF inhibitors (n=111) or a combination of dabrafenib and trametinib (n=31)
- Clinicopathologic factors were correlated with the response to MAPK inhibitors and survival
- Median follow-up: ...